|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Tempest Therapeutics, Inc (TPST) |
|
|
$1.06 0.00 (0.00%) as of 4:30 Fri 6/25
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
6,640,000 |
| Market
Cap: |
7.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.06 - $1.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Versant Vantage Ii Gp-Gp, Llc |
10% Owner |
– – • |
2022-04-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,118,644 |
|
- |
|
| Woiwode Thomas |
Director |
– • • |
2022-04-29 |
4 |
B |
$2.36 |
$5,000,000 |
I/I |
2,118,644 |
2,118,644 |
2.25 |
- |
|
| Dubensky Thomas W. |
President |
• • – |
2022-01-07 |
4 |
B |
$4.78 |
$9,560 |
D/D |
2,000 |
113,343 |
2.81 |
- |
|
| Whiting Samuel |
Chief Medical Officer |
• – – |
2022-01-06 |
4 |
B |
$4.80 |
$8,168 |
D/D |
1,700 |
1,901 |
2.74 |
- |
|
| Rock Springs Capital Master Fund Lp |
10% Owner |
– – • |
2021-12-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
823,654 |
|
-100% |
|
| Whiting Samuel |
Chief Medical Officer |
• • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
201 |
201 |
|
- |
|
| Dubensky Thomas W. |
President |
• • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
111,343 |
111,343 |
|
- |
|
| Woiwode Thomas |
|
• • • |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
2,176,411 |
7,377 |
|
- |
|
| Xu Stella |
|
• • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
579,710 |
579,710 |
|
- |
|
| Lorenzo Pierre |
Corporate Controller |
• • – |
2021-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
53 |
53 |
|
- |
|
| Whitcomb Randall W |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,784 |
15,784 |
|
- |
|
| Mohideen Pharis |
Chief Medical Officer |
• – – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,440 |
7,440 |
|
- |
|
| Aldrich Richard |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
755 |
6,169 |
|
- |
|
| Owens Julia C. |
President and CEO |
• • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
74,400 |
74,400 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
I/I |
23,684 |
23,684 |
|
- |
|
| Gallagher Carol Giltner |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,249 |
8,249 |
|
- |
|
| Fisher Mary |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
355 |
3,319 |
|
- |
|
| Kozin Marc D |
Director |
– • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
831 |
7,740 |
|
- |
|
| Aldrich Richard |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
14,558 |
81,220 |
|
- |
|
| Fisher Mary |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,851 |
44,460 |
|
- |
|
| Kozin Marc D |
Director |
– • – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
16,014 |
103,647 |
|
- |
|
| Fisher Mary |
Director |
– • – |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,510 |
37,609 |
|
- |
|
| Kozin Marc D |
Director |
– • – |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,880 |
87,633 |
|
- |
|
| Aldrich Richard |
Director |
– • – |
2018-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
11,709 |
66,662 |
|
- |
|
| Aldrich Richard |
Director |
– • – |
2018-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
13,101 |
54,953 |
|
- |
|
227 Records found
|
|
Page 1 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
